Anti-IL23
PreclinicalSmall molecule
Anti-IL23 is one of 36 small molecule programs targeting Skin Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Skin Disease
#DrugCompanyPhaseTrials
1Ilumya
Sun Pharmaceutical Industries, Inc.Approved
Zyvox
PfizerApproved
Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Allegra
CChattem
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Viagra
VViatris Specialty LLC
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Minocin
TTriax
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-IL23. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PProf. Dr. Stephan Weidinger